Abstract:Objective: During Toll-like receptor 4 signaling, the Toll/interleukin-1 receptor domain is essential for interactions with downstream Toll/interleukin-1 receptor domain-containing adaptor proteins. The aim of this study is to investigate the role of the Toll/interleukin-1 receptor domain in the Toll-like receptor 4 signaling pathway during hepatic ischemia and reperfusion injury.Design: We genetically blocked the function of Toll/interleukin-1 receptor domain in mice and examined the effect on Toll-like receptor 4 signaling and the response to hepatic ischemia and reperfusion.Setting: University research laboratory.Subjects: Male BALB/c mice.Interventions: Male BALB/c mice were hydrodynamically administrated the target gene plasmid pTIR-IRES2-EGFP, empty vector containing enhanced green fluorescent protein, or normal saline. Animals underwent 90 minutes of partial hepatic ischemia, followed by 6 or 24 hours of reperfusion. Hepatic injury was assessed by measuring serum alanine transaminase, hepatic histology, and malondialdehyde. The expression of inflammatory cytokines and nuclear factor-B phosphorylation was examined in liver tissues. Hepatic apoptosis was evaluated by caspase-3 assays, terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick-end labeling staining, and the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase.Measurements and Main Results: Blocking the Toll/interleukin-1 receptor domain resulted in markedly lower serum alanine transaminase levels, reduced histologic injury, and lower malondialdehyde levels following 6 or 24 hours of hepatic reperfusion than mice receiving the vector alone or normal saline. Anti-Toll/interleukin-1 receptor treatment also reduced Toll-like receptor 4 expression and disrupted Toll/interleukin-1 receptor-Toll/interleukin-1 receptor interactions in Toll-like receptor 4 signaling pathways. Blocking the Toll/interleukin-1 receptor domain also prevented Toll-like receptor 4-mediated mitogen-activated protein kinase activation (via Jun N-terminal kinase and p38 mitogen-activated protein kinase), an activation that mediated liver ischemia and reperfusion injury via caspase-3 activation, resulting in increased hepatocellular apoptosis. Lastly, blocking the Toll/interleukin-1 receptor domain decreased inflammatory cytokine production by inhibiting nuclear factor-B activation.Conclusions: Toll/interleukin-1 receptor domain inhibition disrupts the interaction of Toll-like receptor 4 with its adaptor proteins, which abrogates downstream signaling pathways and prevents the activation of nuclear factor-B and Jun N-terminal kinase/p38. This reduction in signaling consequently reduces hepatic inflammation, cell apoptosis, and hepatic damage. Toll/interleukin-1 receptor domain-targeted therapy thus represents a new approach to inhibit the intracellular Toll-like receptor 4 signaling pathway and reveals novel therapeutic target sites, which will facilitate the development of specific therapeutic agents.

TAK242 suppresses the TLR4 signaling pathway and ameliorates DCD liver IRI in rats

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Liver X Receptors Activation Attenuates Ischemia Reperfusion Injury of Liver Graft in Rats

T-Cell Immunoglobulin and Mucin Domain 4 (Tim-4) Signaling in Innate Immune-Mediated Liver Ischemia-Reperfusion Injury (Iri)

Augmenter of Liver Regeneration Ameliorates Ischemia-Reperfusion Injury in Steatotic Liver Via Inhibition of the TLR4/NF-κB Pathway.

Activation of Cyclic Adenosine Monophosphate-Dependent Protein Kinase a Signaling Prevents Liver Ischemia/reperfusion Injury in Mice

TAK-242, a Toll-Like Receptor 4 Antagonist, Against Brain Injury by Alleviates Autophagy and Inflammation in Rats

TAK-242, an Antagonist for Toll-like Receptor 4, Protects against Acute Cerebral Ischemia/Reperfusion Injury in Mice

Toll-like Receptor 4 Inhibitor TAK-242 Improves Fulminant Hepatitis by Regulating Accumulation of Myeloid-Derived Suppressor Cell.

Endogenous Danger Signals Trigger Hepatic Ischemia/Reperfusion Injury Through Toll-Like Receptor 4/nuclear Factor-Kappa B Pathway

TLR4 signalling in ischemia/reperfusion injury: a promising target for linking inflammation, oxidative stress and programmed cell death to improve organ transplantation outcomes

Protection Against Hepatic Ischemia/reperfusion Injury Via Downregulation of Toll-Like Receptor 2 Expression by Inhibition of Kupffer Cell Function

Optimized Postconditioning Algorithm Protects Liver Graft after Liver Transplantation in Rats.

Bone marrow and non-bone marrow TLR4 regulates hepatic ischemia/reperfusion injury.

IL-4 Alleviates Ischaemia-Reperfusion Injury by Inducing Kupffer Cells M2 Polarization Via STAT6-JMJD3 Pathway after Rat Liver Transplantation

Inhibiting the Toll-Like Receptor 4 Toll/interleukin-1 Receptor Domain Protects Against Hepatic Warm Ischemia and Reperfusion Injury in Mice.

Pyrrolidine Dithiocarbamate Added to University of Wisconsin Solution Inhibits Reperfusion Injury after Orthotopic Liver Transplantation in Rats.

Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling

Pretreatment Donors after Circulatory Death with Simvastatin Alleviates Liver Ischemia Reperfusion Injury Through a KLF2-Dependent Mechanism in Rat

TAK-242 protects against oxygen-glucose deprivation and reoxygenation-induced injury in brain microvascular endothelial cells and alters the expression pattern of lncRNAs

Triiodothyronine Attenuates Hepatic Ischemia/reperfusion Injury in a Partial Hepatectomy Model Through Inhibition of Proinflammatory Cytokines, Transcription Factors, and Adhesion Molecules